Table of Contents

company-logo

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Ryvu Therapeutics Dividend Announcement

• Ryvu Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Ryvu Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Ryvu Therapeutics Dividend History

Ryvu Therapeutics Dividend Yield

Ryvu Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Ryvu Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Ryvu Therapeutics Financial Ratios

P/E ratio-9.75
PEG ratio0.29
P/B ratio4.55
ROE-40.49%
Payout ratio0.00%
Current ratio3.32
Quick ratio3.29
Cash Ratio1.19

Ryvu Therapeutics Dividend FAQ

Does Ryvu Therapeutics stock pay dividends?
Ryvu Therapeutics does not currently pay dividends to its shareholders.
Has Ryvu Therapeutics ever paid a dividend?
No, Ryvu Therapeutics has no a history of paying dividends to its shareholders. Ryvu Therapeutics is not known for its dividend payments.
Why doesn't Ryvu Therapeutics pay dividends?
There are several potential reasons why Ryvu Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Ryvu Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Ryvu Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Ryvu Therapeutics a dividend aristocrat?
Ryvu Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Ryvu Therapeutics a dividend king?
Ryvu Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Ryvu Therapeutics a dividend stock?
No, Ryvu Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Ryvu Therapeutics stocks?
To buy Ryvu Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Ryvu Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.